Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
OwnerWolfgang Eisertinventor
Life of this patent
Estimating the term…
Abstract
A method of treatment of the human or non-human animal body for treating fibrin-dependent microcirculation disorders is disclosed, for example, microcirculation disorders caused by metabolic diseases, inflammatory reactions or autoimmune diseases; peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation comprising administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing a pyrimido-pyrimidine selected from dipyridamole, mopidamol and the pharmaceutically acceptable salts thereof, and the use of said pyrimido-pyrimidine for the manufacture of a corresponding pharmaceutical composition.
Claims15
A method for treating or preventing in a mammal fibrin-dependent microcirculation disorders or disease states where such microcirculation disorders are involved comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a pyrimido-pyrimidine selected from dipyridamole, mopidamol, and the pharmaceutically acceptable salts thereof alone in a monopreparation.
A method for treating in a mammal fibrin-dependent microcirculation disorders or disease states where such microcirculation disorders are involved comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a pyrimido-pyrimidine selected from dipyridamole, mopidamol, and the pharmaceutically acceptable salts thereof in combiation with an agent selected from the group consisting of:
- acetylsalicylic acid (ASA), clopidogrel, ticlopidine and the pharmaceutically acceptable salts thereof, fibrinogen receptor antagonists, heparin, heparinoids, antithrombins, ACE inhibitors, Angiotensin II antagonists, calcium-antagonists and lipid-lowering agents;
- wherein ASA is administered orally in a daily dosage of 10 to 30 mg.
Dependencies are inferred from the claim text.